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depends on the intake of methyl-donor nutrients1–3
Catarina Sousa Guerreiro, Bruno Carmona, Susana Gonc¸alves, Elisabete Carolino, Paulo Fidalgo, Miguel Brito,
Carlos Nobre Leita˜o, and Marília Cravo
ABSTRACT
Background: Polymorphisms located in genes involved in the me-
tabolism of folate and some methyl-related nutrients are implicated
in colorectal cancer (CRC).
Objective: We evaluated the association of 3 genetic polymor-
phisms [C677T MTHFR (methylene tetrahydrofolate reductase),
A2756G MTR (methionine synthase), and C1420T SHMT (serine
hydroxymethyltransferase)] with the intake of methyl-donor nutri-
ents in CRC risk.
Design: Patients with CRC (n 196) and healthy controls (n 200)
matched for age and sex were evaluated for intake of methyl-donor
nutrients and the 3 polymorphisms.
Results: Except for folate intake, which was significantly lower in
patients (P  0.02), no differences were observed in the dietary
intake of other methyl-donor nutrients between groups. High intake
of folate (406.7 g/d) was associated with a significantly lower
risk of CRC (odds ratio: 0.67; 95% CI: 0.45, 0.99). The A2756G
MTR polymorphism was not associated with the risk of developing
CRC. In contrast, homozygosity for the C677T MTHFR variant (TT)
presented a 3.0-fold increased risk of CRC (95% CI: 1.3, 6.7). Sim-
ilarly, homozygosity for the C1420T SHMT polymorphism also had
a 2.6-fold increased risk (95% CI: 1.1, 5.9) of developing CRC.
When interactions between variables were studied, low intake of all
methyl-donor nutrients was associated with an increased risk of CRC
in homozygous participants for the C677T MTHFR polymorphism,
but a statistically significant interaction was only observed for folate
(odds ratio: 14.0; 95% CI: 1.8, 108.5). No significant associations
were seen for MTR or SHMT polymorphisms.
Conclusion: These results show an association between the
C677T MTHFR variant and different folate intakes on risk of
CRC. Am J Clin Nutr 2008;88:1413– 8.
INTRODUCTION
Colorectal cancer (CRC) is a complex disease that involves
multiple genetic and nutritional factors (1). Among the latter,
folate was shown to play a preventive role in colorectal carcino-
genesis probably because of its involvement in the processes of
DNA methylation and synthesis (2). Other nutrients such as
methionine, vitamin B-6, and vitamin B-12, which interact met-
abolically with folate in this process, may also influence the risk
of CRC (3). In some of those studies the observed inverse asso-
ciation between folate status and CRC risk was further modified
by genetic polymorphisms of the enzymes involved in folate
metabolism, most notably methylene tetrahydrofolate reductase
(MTHFR). A common C677T substitution in the MTHFR gene,
converting alanine to valine, results in a thermolabile enzyme
with decreased activity (4). Numerous studies have shown that
this variant (TT) is associated to a decreased risk of CRC, but
only when folate status is normal or high. As stated by Crott and
Mason (4), MTHFR polymorphism is possibly the only known
gene polymorphism that switches from being a risk factor to a
protective one depending on nutrient status. In addition, because
folate metabolism involves the interconversion of different co-
enyzymatic forms of the vitamin through multiple cycles, as well
as feedback mechanisms between cycles, it is also important to
evaluate the joint influence that other polymorphisms in genes
involved in these cycles might exert. Methionine synthase re-
quires vitamin B-12, as methylcobalamin, as a cofactor. A vari-
ant in this gene was described, A2756G, which results in the
substitution of aspartate by glycine. Studies on colorectal neo-
plasia are inconsistent, with some studies showing that GG ge-
notype is associated to a decreased risk of CRC (5, 6), yet a
possible increased risk of colorectal adenoma (7). No associa-
tions with diet were sought in those previous studies. Serine
hydroxymethyltransferase (SHMT) is a pyridoxal phosphate
(B6)–dependent enzyme. A polymorphism was identified,
C1420T, which results in the substitution of the amino acid
leucine by phenylalanine. The functional significance of this
polymorphism is still unknown. A single study has examined the
influence that this polymorphism might have in the risk of CRC
and found no association. Again, no associations with dietary
intake were examined (8). Therefore, it was the aim of this case-
control study to evaluate the role of these polymorphisms in
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defining CRC risk either alone or in association with specific
nutrient intakes and other genotypes.
SUBJECTS AND METHODS
Study population
Study participants were described previously (9). Briefly this
was a case-control study, performed at the Instituto Portugueˆs de
Oncologia de Lisboa Francisco Gentil EPE. The study was ap-
proved by the Scientific and Ethics committees of the Instituto
Portugueˆs de Oncologia de Lisboa Francisco Gentil EPE, and
both patients and controls gave their informed written consent to
participate in the study.
The patients’ group is composed of 196 subjects [104 men, 92
women; age (x SD): 64.2 11.3 y) with a histologic diagnosis
of CRC, whereas the control group included 200 healthy blood
donors volunteers recruited from the same institute, with a sim-
ilar sex and age distribution (106 men, 94 women; mean age: 62.2
 12.1 y) and with no previous history of cancer at any site.
Colonoscopy was not performed in controls to exclude CRC, but
all subjects were symptom free, and no anemia was present. One
hundred sixty-nine (86.5%) of 196 patients had a recent diagno-
sis of CRC, whereas the remaining 27 (13.5%) were being treated
for a disease relapse. For previous therapies, 119 (60.7%) of 196
patients had not received any form of treatment, 28 (14.3%) had
already undergone surgery, 13 (6.6%) had received pelvic radio-
therapy, 11 (5.6%) had received1 cycles of chemotherapy, and
the remaining 25 (12.8%) had undergone combined forms of
treatment. Tumor-node-metastasis staging was as follows: stage
I, 24 (13.5%) of 178; stage II, 64 (35.9%) of 178; stage III, 53
(29.8%) of 178; and stage IV, 37 (20.8%) of 178.
Nutritional intake evaluation
For quantifying folate, vitamin B-6, vitamin B-12, glycine,
methionine, serine, and alcohol intake, we used a food-frequency
questionnaire (10), validated for the Portuguese population. Par-
ticipants were asked to recall their habits in the year before CRC
diagnosis in patients or in the year before interview in controls.
Colored photographs of most food items, showing 3 different
portions sizes, as well as measuring cups and spoons, were used
to facilitate quantification of intake. Type and quantity of food
intake was then analyzed in a modified database FOOD PRO-
CESSOR SOFTWARE, version 7 (ESHA Research Inc, Salem,
OR), including some Portuguese food items, which allows the
quantification of different macronutrients and micronutrients.
Nutrient values were calculated from foods and supplements (11
of 196 patients and none of the controls were taking supple-
ments). Physical activity in the year before cancer diagnosis in
patients or in the year before interview in controls was assessed
with the use of Jackson’s questionnaire (11), which categorized
subjects in 3 different levels: low (0), intermediate (1), and high
(2). Smoking habits were recorded as the number of cigarettes per
day.
Genotype data
Whole blood samples were collected and stored in 3-mm
Cards Kit papers. DNA extraction was done with the use of
Generation Capture Card Kit, DNA Purification, DNA Elution
(Gentra Systems Inc, Minneapolis, MN). The GAC/GTC poly-
morphism at codon 677 of the MTHFR gene and the A2756G
polymorphism from MTR (5,10-methylenetetrahydrofolate re-
ductase) were genotyped with the use of an “Assays-by-Design”
TaqMan allelic discrimination assay (Applied Biosystems, Fos-
ter City, CA). The SHMT polymorphism C1420T was genotyped
with the use of TaqMan probes designed with BEACON DE-
SIGNER 5.0 software (Premier Biosoft, Palo Alto, CA). Probes
for the C allele (CAGAGGGAAGAGAGAGGCGAAGC) and T
allele (CAGAGGGAAGAAAGAGGCGAAGC) and for the
forward primer (GAAAGAGTTCAAGGAGAGACT) and the
reverse primer (CTCCTTTAGAAGTCAGGCAG) were used.
Polymerase chain reaction (PCR) was performed with mixes
consisting of 4L of genomic DNA, 10L of Taqman Universal
PCR Master Mix (Applied Biosystems), 1L of 20 assay mix,
and ddH2O 20 L of final volume. The following amplifica-
tion protocol was used: denaturation at 95 °C for 10 min, fol-
lowed by 40 cycles of denaturation at 92 °C for 15 s, and anneal-
ing and extension at 60 °C for 1 min. All the reactions were
performed in the iCycler iQ Multicolor Real Time PCR Detec-
tion System (Bio-Rad, Hercules, CA). After PCR, the genotype
of each sample was attributed automatically by measuring the
allelic-specific fluorescence on the equipment software.
Subjects were classified as homozygous for the variant if they
carried 2 mutated alleles, heterozygous if they carried only 1
mutated allele, and finally homozygous for the wild type when
they had no mutant alleles. When analyzing the interaction be-
tween genetic and nutritional variables, the median value for
each nutrient was considered. We did not use the dietary refer-
ence intake because, for most nutrients, the percentage of sub-
jects who ingested the dietary reference intake was higher than
80%, for both patients and controls.
Statistical methods
Statistical analysis was performed with the use of SPSS ver-
sion 15.0 for WINDOWS (SPSS Inc, Chicago, IL). Data were
expressed as mean  SD, as number of subjects and (percent-
age), or as odds ratio (OR) and 95% CI. Bivariate analyses were
conducted with the use of the Student’s t test or Mann-Whitney
test for continuous and the chi-square test for categorical vari-
ables. Multiple logistic regression was used to assess the vari-
ables related to CRC risk. Significance of interactions was as-
sessed with the likelihood ratio test comparing the model with
interaction with one containing only the main effects for 2 vari-
ables. Statistical significance was established at P 0.05.
RESULTS
Subjects characteristics and lifestyle habits
Both groups were similar for age and sex distribution. Some
patients (23%) had a positive familial history of CRC in first- or
second-degree relatives, contrasting with only 8% of the control
population (P 0.001; OR: 3.4; 95% CI: 1.85, 6.29). No differ-
ences were found in smoking habits between the groups (P 
0.05), but compared with controls, patients had a significantly
lower body mass index (in kg/m2: 27.03.9 compared with 25.6
 4.2; P 0.01) and were significantly less active (P 0.001).
However, exercise per se did not influence the risk of developing
CRC (OR: 0.78; 95% CI: 0.53, 1.1).
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The daily nutritional intake of folate, vitamins B-12 and B-6,
glycine, methionine, serine, and alcohol is shown in Table 1. No
significant differences were observed between cases and con-
trols except for folate intake that was significantly lower in pa-
tients (P 0.02). Analyzing the risk associated with this nutrient
intake, we observed a risk (OR) of 0.67 (95% CI: 0.45, 0.99) for
participants with a high intake of folate (406.7 g/d). Alcohol
consumption was higher in patients, but the difference did not
reach statistical significance, because 35.2% of the patients and
38.5% of the controls did not drink any type of alcoholic bever-
age. However, if we consider only alcohol drinkers in both
groups, we observed that daily intake was significantly higher in
patients than in controls: 38.8 g/d compared with 31.0 g/d, re-
spectively (OR: 1.97; 95% CI: 1.19, 3.26). When analyzing the
concomitant influence of2 nutrients in modulating the risk of
CRC, no interaction between variables was found, except for a
high alcohol intake combined with low folate ingestion, which
was associated, to a statistically marginal degree, with a higher
risk of developing CRC (OR: 1.47; 95% CI: 0.94, 2.30; P 
0.08).
Polymorphism genotypes
The genotype frequencies for polymorphisms are reported in
Table 2. Genotype distributions among controls were in agree-
ment with the Hardy Weinberg equilibrium with the exception of
the C677T MTHFR polymorphism. The variant allele frequen-
cies for C677T MTHFR, A2756G MTR, and C1420T SHMT
genotypes were 31.2%, 16.7%, and 26.5%, respectively, in con-
trols, and 32.7%, 15.1%, and 28.6%, respectively, in cases.
A2756G MTR per se was not associated with increased risk of
CRC (Table 2). In contrast, homozygous participants for the
C677T MTHFR variant (TT) showed a 3.0-fold increased risk of
CRC (OR: 3.01; 95% CI: 1.3, 6.7). Similarly, homozygosity for
the C1420T SHMT polymorphism had a 2.6-fold increased risk
(95% CI: 1.1, 5.9) of developing CRC. None of the variant alleles
of the 3 polymorphisms was associated with the risk of CRC.
Considering only the patient group, we did not observe any
correlation between genotype and sex, tumor location (colon or
rectum), stage of disease, or familial history of CRC. We also
evaluated the interaction between the 3 polymorphisms in mod-
ulating the risk of CRC. For each sex no significant interaction
was observed between the different genotypes (data not shown).
Diet and polymorphisms interaction
The interaction between the intake of several methyl-donor
nutrients and alcohol and the C677T MTHFR polymorphism is
shown in Table 3. Interestingly, we observed that a low intake of
all methyl-donor nutrients was associated with increased risk of
developing CRC in TT carriers, but a significant interaction was
only observed for folate (OR: 14.0; 95% CI: 1.8, 108.5). For
alcohol intake no modulating effect was observed. For the
A2756G MTR and C1420T SHMT polymorphisms, no signifi-
cant interactions were observed with any of the nutrients studied.
DISCUSSION
The present case-control study focused on the risk of CRC and
the interaction between intake of folate and other methyl-related
nutrients and genetic polymorphisms in folate-metabolizing en-
zymes in a Portuguese population. A number of epidemiologic,
clinical, and animal studies performed during the past 2 decades
strongly support the concept that low folate status predisposes to
colorectal carcinogenesis (12). Biological mechanisms linking
folate depletion to colorectal carcinogenesis include disruption
of nucleotide synthesis, DNA methylation, or both because folate
is the primary intermediary for most methylation reactions in
cellular metabolism (2, 12–15).
Although most studies focus on folate alone, there are other
nutrients, such as vitamin B-6 or vitamin B-12, which are im-
portant coenzymes required for the activity of different enzymes
involved in these methylation cycles such as MTR or SHMT, or
certain essential and nonessential amino acids that also play
important functions in the DNA methylation cycle. For these
reasons, in the present study, we evaluated the influence of these
methyl-related nutrients either alone or in interaction with the
folate-metabolizing enzymes MTHFR, MTR, and SHMT in the
risk of CRC.
Our data show that, except for folate, none of the other nutri-
ents that we analyzed alone or in conjunction with others influ-
enced the risk of CRC. For folate, we observed that an intake of
folate406.7g/d reduced the risk of CRC in30% (OR: 0.67;
95% CI: 0.45, 0.99). This is in agreement with most prospective
epidemiologic studies published so far (16, 17), although re-
cently published studies raise the hypothesis whether a high
folate intake in patients harboring premalignant lesions, ie, colo-
rectal adenomas, might actually increase the risk of CRC (7, 18).
TABLE 1




(n 200) P OR (95% CI)2
Vitamin B-6 (mg/d) 2.83 1.063 2.85 0.98 NS 0.77 (0.50, 1.14)
Vitamin B-12 (g/d) 14.5 9.1 14.3 8.23 NS 0.98 (0.66, 1.45)
Folate (g /d) 401.6 161.9 434.3 161.3 0.02 0.67 (0.45, 0.99)
Glycine (mg/d) 5.39 2.8 5.10 2.34 NS 1.00 (0.68, 1.50)
Methionine (mg/d) 2.85 1.28 2.78 1.13 NS 0.99 (0.67, 1.50)
Serine (mg/d) 5.15 2.20 5.14 1.95 NS 0.89 (0.59, 1.30)
Alcohol (g/d) 25.17 39.8 19.14 43.42 NS 1.08 (0.73, 1.61)
1 Differences in nutrients were determined with the Mann-Whitney test, adjusted for age, sex, and colorectal cancer history. OR, odds ratio.
2 OR was determined with the values above or below the nutrient median intake. The cutoffs were as follows: vitamin B-6, 12.5 mg; vitamin B-12, 12.5
g; folate, 406.7 g; methionine, 2.58 mg; serine, 4.86 mg; glycine 4.68 mg; and alcohol, 3.4 g/d.
3 x  SD (all such values).
INFLUENCE OF DIET AND POLYMORPHISMS IN CRC PATIENTS 1415






However, we would like to strengthen that this increased risk of
CRC is observed when pharmacologic doses of folic acid (the
synthetic form of folate with greater availability) is used and not
with dietary folate intake alone. In regard to the influence that
genetic polymorphisms exert in the risk of CRC, the polymor-
phism C677T of the MTHFR gene is probably the most studied,
but its relation with the risk of CRC is still unclear. The presence
of this polymorphic variant (TT) was shown to reduce in vitro the
enzyme activity to 30% (19), which may result in a significantly
lower DNA methylation in TT carriers than in CC and CT sub-
jects (20).
Contrary to most previously published studies, which report a
50% reduction in CRC risk in persons carrying the TT genotype,
we report that the TT genotype was associated with an increased
risk of CRC (OR: 3.01; 95% CI: 1.3, 6.7). However, a critical
examination of previously published studies suggests that the
protective effect of the TT genotype seems to largely depend on
folate intake. Thus, among the first studies performed in North-
ern American countries, Chen et al (21) found that the TT geno-
type could actually increase the risk of CRC in men with high
alcohol consumption (OR: 1.56; 95% CI: 0.65, 3.81). Alcohol is
a known antagonist of folate metabolism and similarly to folate
depletion; chronic alcohol abuse was shown to result in DNA
hypomethylation (22). In a later study, Ma et al (23) showed that
the TT genotype exhibited a protective effect in the risk of CRC
but only in patients with a high folate intake. In men with low
folate intake, the TT genotype was actually associated with an
increased risk of developing CRC (OR: 1.33; 95% CI: 0.34,
5.17). Note that all the studies performed in North America since
then (which unequivocally show a protective effect of the TT
genotype) were performed after the mandatory fortification of
enriched uncooked cereal grains with folic acid. Finally, we also
have to consider that 35–50% of US adult citizens regularly
consume a vitamin supplement, most of which provide 400g of
folic acid per pill. All of the above considerations are possible
explanations for the fact that since 1998-2000 all studies per-
formed in the United States that examined the effect of C677T
MTHFR polymorphism found a protective effect for the TT ge-
notype because folate intake was in the high range for most if not
all persons (23, 24). In the study published by Le Marchand et al
(25) the researchers observed that total folate intake was between
500 and 600 g/d, whereas in the present series we observed an
intake400g/d. This different intake is a plausible explanation
for the different results obtained in studies coming from Europe
(26–28), Mexico (29), or even Australia (30) where the TT
genotype was actually found to be associated with an increased
risk of CRC. In neither Europe nor Australia has fortification
with folic acid been implemented; therefore, it is likely that folate
status is substantially lower than in the countries were fortifica-
tion has taken place. In further support of this hypothesis, when
we examined the interaction between folate intake and MTHFR
polymorphism, we observed that low folate intake was particu-
larly deleterious in TT carriers (OR: 14.0; 95% CI: 1.8, 108.5).
The reason for not having observed a protective effect of folate
intake in TT carriers probably relates to the fact that in our
population folate intake might not reach the amount required that
would change TT genotype into a protector factor.
In the present study we also examined the effect of a recently
described polymorphism in MTR, A2756G (31). Similar to our
present study, Ma et al (5) and Marchand et al (25) observed that
TABLE 2




(n 200) P2 OR (95% CI)3
% (n) % (n)
MTHFR
CC/CT 86.7 (170) 95.5 (191) 0.002 1
TT 13.3 (26) 4.5 (9) 3.01 (1.3, 6.7)
Allele C 67.3 (264) 68.8 (275) NS 1
Allele T 32.7 (128) 31.2 (125) 1.07 (0.79, 1.44)
MTR
AA/AG 98.0 (192) 98.0 (196) NS 1
GG 2.0 (4) 20.0 (4) 0.77 (0.18, 3.3)
Allele A 84.8 (333) 84.9 (339) NS 1
Allele G 15.1 (59) 16.7 (67) 0.90 (0.61, 1.32)
SHMT
CC/CT 90.0 (177) 95.5 (191) 0.04 1
TT 10.0 (19) 4.5 (9) 2.6 (1.1, 5.9)
Allele C 71.4 (280) 73.5 (294) NS 1
Allele T 28.6 (112) 26.5 (106) 1.11 (0.81, 1.52)
1 MTHFR, methylene tetrahydrofolate reductase; MTR, 5,10-
methylenetetrahydrofolate reductase; SHMT, serine hydroxymethyltrans-
ferase; OR, odds ratio.
2 Determined with the chi-square test.
3 Wild-type–heterozygote genotype was the reference category for OR
calculation (multiple regression). OR was adjusted for age, sex, and colo-
rectal cancer history.
TABLE 3
Odds ratio (OR) of colorectal cancer according to C677 MTHFR
(methylene tetrahydrofolate reductase) genotype and diet1
C677T MTHFR P for
interactionCC/CT TT
Vitamin B-6
High 0.83 (0.55, 1.26)2 1.77 (0.67, 4.68) NS
Low 1 7.22 (1.6, 32.6)
Vitamin B-12
High 1.01 (0.67, 1.53) 2.71 (0.9, 8.0) NS
Low 1 3.95 (1.2, 12.4)
Folate
High 0.77 (0.51, 1.17) 1.50 (0.59,3.8) 0.05
Low 1 14.0 (1.8108.5)
Glycine
High 1.1 (0.7, 1.6) 2.0 (0.7,5.3) NS
Low 1 8.2 (1.8, 36.9)
Methionine
High 1.1 (0.75, 1.76) 2.1 (0.8, 6.2) NS
Low 1 5.9 (1.6, 1.3)
Serine
High 0.92 (0.6, 1.4) 1.79 (0.63, 5.14) NS
Low 1 5.7 (1.6, 20.4)
Alcohol
High 1.1 (0.72, 1.6) 3.5 (1.1, 11.3) NS
Low 1 3.2 (1.1, 9.5)
1 Combined genotype wild type–heterozygote (CC/CT) and low intake
were the reference category for OR calculation (multiple regression). OR was
adjusted for age, sex, and colorectal cancer history and determined with the
values above or below the nutrient median intake. The cutoffs were as fol-
lows: vitamin B-6, 12.5 mg; vitamin B-12, 12.5 g; folate, 406.7 g; me-
thionine, 2.58 mg; serine, 4.86 mg; glycine 4.68 mg, for alcohol, 3.4g/d.
2 OR; 95% CI in parentheses (all such values).
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MTR polymorphism was not associated with CRC risk, nor was
there a significant interaction with any of the methyl-donor nu-
trients analyzed.
Finally, we also studied the C1420T1 SHMT1 polymorphism.
To our knowledge, there is only one study that examined the
relation between SHMT1 genotype and risk of CRC, and it did not
observe any interaction (7). Recently, Van den Donk et al (32)
studied the relation between this polymorphism, diet, and colo-
rectal adenomas and concluded that the SHMT1 C1420T poly-
morphism does not play a role in colorectal carcinogenesis. One
hypothesis for this lack of association, which was postulated by
Chen et al (8), is that SHMT2 (another isoform of the same
enzyme) can also supply the one-carbon units required for cyto-
solic folate metabolism. In the present series we observed that
this polymorphism was associated with an increased risk of de-
veloping CRC, although the strength of our observation is limited
by the small number of participants homozygous for the variant
(n  9). Because the functional significance of this polymor-
phism is not yet known and because of the small numbers of
homozygous participants, these results will need further confir-
mation.
In conclusion, in the present study we show that the C677T
MTHFR polymorphism modifies the risk of developing CRC
according to folate intake. To our knowledge, the influence of
this genetic polymorphism was never examined in Southern Eu-
ropean countries where pattern of folate and other methyl-donor
nutrients, as well as alcohol, is certainly different from Northern
Europe or American countries. Because mandatory folic acid
fortification was never implemented in our country and vitamin
supplements are not popular, it is believed that our population has
a relatively low folate intake. This is a plausible explanation for
the fact that, in our population, the TT genotype is associated with
increased risk of developing CRC, particularly in participants
with low folate intake (Table 3).
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